The pharmaceutical industry is under increasing pressure to accelerate product development and enhance efficiency while maintaining a focus on sustainability. A key area for achieving this balance is solvent selection, as solvents play a vital role in various pharmaceutical processes but are significant contributors to environmental impact. Optimising solvent selection is crucial for improving process efficiency and reducing environmental footprint. Computer-Aided Mixture/Blend Design (CAMbD) offers a transformative approach to solvent selection, enabling systematic evaluation based on economic and environmental performance indicators. This leads to more efficient, cost-effective, and environmentally friendly processes.
The industry has traditionally relied on empirical knowledge and iterative experimentation for solvent selection, a method that is both time-consuming and expensive. The environmental footprint of solvents in pharmaceutical processes presents a significant challenge, with a need to find solutions that are both effective and compliant with stringent environmental regulations. The balance between optimising solvent performance and minimising environmental impact is complex, requiring a strategic and systematic approach.
The Sargent Centre’s Mohamad H. Muhieddine conducted a case study focusing on the solvent selection for the integrated synthesis, crystallisation, and isolation of mefenamic acid, a drug commonly used for mild pain treatment. Using CAMbD, the study achieved an almost completely pure product without the usual environmental burden. This case study illustrates how advanced tools like CAMbD can guide the pharmaceutical industry in making smarter solvent choices, achieving high product quality while minimising waste. Mohamad now applies his expertise in system modelling and simulations full-time at GSK.
Incorporating CAMbD into solvent selection goes beyond compliance with regulatory pressures; it represents a proactive strategy that enhances overall process design. CAMbD enables multi-objective optimization, helping companies understand and balance trade-offs between key performance indicators such as cost, yield, and environmental impact. This holistic approach provides a deeper understanding of the interdependencies between these KPIs, leading to more robust and sustainable process designs. In early-stage pharmaceutical process development, CAMbD can model solvent behaviour across different scenarios, optimising yield while minimising waste and reducing overall process costs. This innovative approach paves the way for greener, cleaner production processes in the pharmaceutical industry.
